They are starting late stage clinical trials in various countries and the company have already received $60 million in orders, from countries in Asia Pacific, Europe as well as the US, who have already purchased the drug with more to come.

With a good product like Tpoxx, sound financials, n the recent news of the U.S. government exercising the option to acquire $26 million of the company's intravenous monkeypox treatment and fund a post-marketing study for the therapy, amongst other things, are fuelling the continued momentum upwards.

Such companies n their meds are very much needed during these unfortunate pandemic times. Still we have to trade cautiously as prices of pharma start-ups at this stage can swing either way. Therefore a good short term trade IMHO.